LAMEA Indapamide Market Size, Share, Impressive Industry Growth, Analysis Report 2028

 

The LAMEA indapamide market is estimated to grow significantly during the forecast period. The factors contributing to the growth of the indapamide market include rising cases of diabetes and hypertension among the population. According to the International Diabetes Federation (IDF), Brazil and Mexico are the two countries with a higher number of diabetes cases registered in the region. In Mexico, an estimated 12 million cases were registered in 2017. Additionally, the diabetes cases are expected to rise by 35% to an estimated 16 million cases by 2045 in Mexico. Moreover, according to the World Health Organization (WHO), diabetes is the second-most common cause of mortality in Mexico. Hence, indapamide drugs have great potential to offer for diabetes in the market of the RoW region. Some of the major factors that are contributing to the increasing cases of diabetes include rapid urbanization and changing lifestyles across the region.

(Get 25% Discount on Buying this Report)

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/lamea-indapamide-market

The LAMEA indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg indapamide and 2.5 mg indapamide. Among these, the market for 1.25 mg medicine held a significant share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

Some of the global companies operating in the LAMEA indapamide market include ANI Pharmaceuticals, Inc., Apotex Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Mylan N.V., and others. The market players are considerably contributing to market growth by adopting various strategies to stay competitive in the market.

Latin America and Middle & Africa (LAMEA) Indapamide Market- Segmentation

By Product

·         1.25 MG

·         2.5 MG

By Application

·         High Blood Pressure

·         Heart Failure

·         Others

A full report of Latin America and Middle & Africa (LAMEA) Indapamide Market is available at: https://www.omrglobal.com/industry-reports/lamea-indapamide-market

Latin America and Middle & Africa (LAMEA) Indapamide Market– Segment by Region

·         Latin America

·         Middle East

·         Africa

Company Profiles

·         ANI Pharmaceuticals, Inc.

·         Glenmark Pharmaceuticals Ltd.

·         Grupo Azevedos

·         Krka Group

·         Mylan N.V.

·         Merck KGaA

·         Sanofi S.A.

·         Sandoz International GmbH

·         Servier Group

·         Teva Pharmaceuticals Industries Ltd.

Reasons to Buying From us –

1.       We cover more than 15 major industries, further segmented into more than 90 sectors.

2.       More than 120 countries are for analysis.

3.       Over 100+ paid data sources mined for investigation.

4.       Our expert research analysts answer all your questions before and after purchasing your report.

 

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

 

Media Contact:

Contact Person: Mr. Anurag Tiwari

Email: anurag@omrglobal.com

Contact no: +91 780-304-0404

Company Name: Orion Market Research